Ligand Discloses 47% Shareholder Support for XOMA Royalty Acquisition
XOMA sits 86% above its 52-week low of $22.29.
Summary
Ligand Pharmaceuticals has disclosed a 47% stake in XOMA Royalty Corporation through voting and support agreements, detailed in a Schedule 13D filing on May 1, 2026. This development provides strong confirmation of shareholder backing for the previously announced merger, where Ligand is set to acquire XOMA for $39 per share in cash plus contingent value rights. This follows the definitive merger agreement announced on April 27 and a subsequent Schedule 13D/A filing on April 29 detailing major shareholder support. The significant 47% commitment from key holders substantially de-risks the acquisition, indicating a high probability of the deal closing. Traders will now monitor the remaining conditions, such as HSR clearance and the final stockholder vote, for the merger's completion.
At the time of this announcement, XOMA was trading at $41.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $501.9M. The 52-week trading range was $22.29 to $42.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.